EUVIMEDEUVIMED entdecken
Crossref

Spirooxadiazoline‐oxindoles derived from imatinib show antimyeloproliferative potential in K562 cells

Liviane D de Azevedo, Debora I Leite, Andressa P de Oliveira, Floriano P S Junior, Rafael F Dantas, Monica M Bastos, Nubia Boechat, Luiz C F Pimentel

Archiv der Pharmazie · 2024

DOI: 10.1002/ardp.202400029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Liviane D de Azevedo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Síntese Orgânica, Fundação Oswaldo Cruz, Farmanguinhos, Rio de Janeiro, Brasil. Hauptthemen laut MEDLINE: Imatinib Mesylate, Oxindoles, Antineoplastic Agents, Cell Survival. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Imatinib mesylate was the first representative BCR‐ABL1 tyrosine kinase inhibitor (TKI) class for the treatment of chronic myeloid leukemia. Despite the revolution promoted by TKIs in the treatment of this pathology, a resistance mechanism occurs against all BCR‐ABL1 inhibitors, necessitating a constant search for new therapeutic options. To develop new antimyeloproliferative substances, we applied a medicinal chemistry tool known as molecular hybridization to design 25 new substances. These compounds were synthesized and biologically evaluated against K562 cells, which express BCR‐ABL1, a constitutively active tyrosine kinase enzyme, as well as in WSS‐1 cells (healthy cells). The new compounds are conjugated hybrids that contain phenylamino‐pyrimidine‐pyridine (PAPP) and an isatin backbone, which are the main pharmacophoric fragments of imatinib and sunitinib, respectively. A spiro‐oxindole nucleus was used as a linker because it occurs in many compounds with antimyeloproliferative activity. Compounds 2a , 2b , 3c , 4c , and 4e showed promise, as they inhibited cell viability by between 45% and 61% at a concentration of 10 µM. The CC 50 of the most active substances was determined to be within 0.8–9.8 µM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylateOxindolesAntineoplastic AgentsCell SurvivalHumansK562 CellsStructure-Activity RelationshipProtein Kinase InhibitorsCell ProliferationMolecular StructureDose-Response Relationship, DrugFusion Proteins, bcr-ablSpiro CompoundsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

PAPPchronic myeloid leukemiaimatinibspiro‐oxindolestyrosine kinase inhibitors

Substanzen

Imatinib MesylateOxindolesAntineoplastic AgentsProtein Kinase InhibitorsFusion Proteins, bcr-ablSpiro Compounds

Autor:innen und Institutionen

  • Departamento de Síntese Orgânica, Fundação Oswaldo Cruz, Farmanguinhos, Rio de Janeiro, Brasil.
  • Fundação Oswaldo Cruz, Laboratório de Bioquímica Experimental e Computacional de Fármacos, Instituto Oswaldo Cruz, Rio de Janeiro, Brasil.

Förderung

  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

Zitieren

APA

de Azevedo, L. D., Leite, D. I., de Oliveira, A. P., Junior, F. P. S., Dantas, R. F., Bastos, M. M., Boechat, N., & Pimentel, L. C. F. (2024). Spirooxadiazoline‐oxindoles derived from imatinib show antimyeloproliferative potential in K562 cells. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400029

Vancouver

de Azevedo LD, Leite DI, de Oliveira AP, Junior FPS, Dantas RF, Bastos MM, et al. Spirooxadiazoline‐oxindoles derived from imatinib show antimyeloproliferative potential in K562 cells. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400029

BibTeX
@article{deAzevedo2024,
  author = {de Azevedo, Liviane D and Leite, Debora I and de Oliveira, Andressa P and Junior, Floriano P S and Dantas, Rafael F and Bastos, Monica M and Boechat, Nubia and Pimentel, Luiz C F},
  title = {Spirooxadiazoline‐oxindoles derived from imatinib show antimyeloproliferative potential in K562 cells},
  journal = {Archiv der Pharmazie},
  year = {2024},
  doi = {10.1002/ardp.202400029}
}
Kostenlos starten →